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Glyco-immuno-oncology
Glyco-immuno-oncology is a relatively new discipline which
has developed from the fusion of three established and
growing fields that are briefly reviewed below [1]. Its
foundations lie in the fact that the human proteome is >50%
glycosylated [2]. This extra glycan information or ‘glyco-code’
allows for glycoform dependent intracellular communication
between cancer cells and immune cells. This niche field is
beginning to reveal translational opportunities that offer great
potential benefits.
Immuno-oncology
It has been a slow-burner but the importance of tumor-
immune crosstalk is now commonly accepted. The success of
immune checkpoint inhibitors in particular has far reaching
and profound consequences for how we think about
translational research and treatment within oncology; the
immune system must now be considered [3]. This new schema
has led to translational research focused on previously
unthinkable and dangerous concepts, such as promoting
angiogenesis and genetic instability, to allow for greater
immune infiltration and neo-antigen expression respectively
[4,5]. This is truly revolutionary.
Glyco-oncology
It is also commonly accepted that tumors express aberrant,
usually truncated glycans, both O and N linked; indeed, these
alterations are considered a hallmark of cancer [6]. These
changes can occur due to specific mutational events, such as in
the case of COSMC [7], but this author, and others, would
argue that in the majority of cases aberrant glycosylation is
brought about by local micro-environmental stress. It is the
only way to explain the relative uniformity of glycophenotype
in, for example, breast cancer, against such a backdrop of
genetic and transcriptomic diversity.
Mechanistically, these stressors can result in damage to
glyco-machinery (include the ER and Golgi), a change in
glycosyltransferase (GST) expression levels (often via
inflammatory mediators) or simply the overproduction of
certain proteins or lack of substrate [8-10]. The impact of
these changes for the cancer can be broadly split into intra-
and extra-cellular effects: i) Intra-cellular effects, range from
driving proliferation to preventing apoptosis, through a variety
of direct and indirect mechanisms; ii) Extra-cellular effects
range from altering adhesion, altered polarity resulting in
proliferation-driving cis-interactions, to immune modulation
[10].
Glyco-immunology
It is still to be commonly recognized that glycans are
important in immunity, certainly outside of infectious disease,
despite nearly one fifth of CD numbers being either lectins or
carbohydrates [11]. There are occasional high impact
publications, however the field is arguably spread too thinly
over too wide a range of pathologies resulting in slightly ad
hoc advancement. Although this can be viewed as a weakness,
this field is truly multidisciplinary and much can be learnt from
this.
For example, it is becoming more and more apparent that
there are shared glycan specific mechanisms at play, regardless
of the underlying disease and its etiology; this is exemplified
by glycan-specific antibodies and lectins that stain both
parasites and tumors [12-14]. Needless to say, a comparative
analysis of the genomics, transcriptomics and proteomics
shows few similarities, however it is through the shared
glycans that we can understand how similar immune
modulatory mechanisms exist [14]. Similar parallels can be
drawn between cancers and other pathogens, changes during
pregnancy and chronic inflammatory disease [15-17].
Why bring these three fields
together?
These three specific fields should be, and are being, brought
together for one main reason: need. As global health
improves, and the impact of infectious disease lessens, cancer
is becoming an increasing health burden.
When carried on commonly over-expressed proteins,
aberrant glycans allow for highly specific targeted therapy
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across multiple cancers [18,19]. Beyond this, understanding
the processes by which aberrant glycans promote tumor
growth and spread opens up a large number of therapeutic
opportunities. For example, engagement of siglecs, carried on
many immune cells has been seen to allow for tumor
progression through a variety of mechanisms [20-23]; these
processes are extremely similar to those used by pathogens to
evade the immune system [24,25]. Another important example
can be found in the galectin field; where galectins potentiate
invasion, facilitate immune evasion and allow for increased
tumorigenic signaling [26]. Perhaps unsurprisingly, the rewards
on offer have driven investment into this field in the forms of
glyco-immune checkpoint therapy, and galectin and glycoform
targeting therapies [27-29].
The hope, beyond oncology, is that mechanisms uncovered
by this need and subsequent cash-injection may help with
other seemingly unrelated pathologies with shared
glycophenotypes. A good example here is idiopathic
pulmonary fibrosis (IPF) and KL-6. KL-6 is an antibody clone
which binds to MUC1 carrying sialylated core 1 or core 2
glycans, and is commonly used as a biomarker for IPF and for
disease progression [30,31]. Although the role of KL-6 in IPF is
not yet well established, the parallels between our work, with
MUC1 carrying sialylated core 1 glycans in breast cancer, and
others, and IPF pathology can be seen [20,32].
Resources
Beyond capital, to drive this and indeed any field forward
requires good tools and resources. Table 1 summarizes the
current tools available to study glycans in both immunology
and oncology. Additionally, I would like to take the opportunity
to highlight several free online resources that are very useful,
especially when approaching this field for the first time.
The CAZy database: Describes the families of structurally
related catalytic and carbohydrate-binding modules of
enzymes that degrade, modify, or create glycosidic bonds [33].
Functional glycomics gateway: A comprehensive and free
online resource provided by the Consortium for Functional
Glycomics (CFG) [34].
Glyco-CD: A manually curated repository of CDs which are
defined as oligosaccharides or lectins [11].
Glyco-domain viewer: A database of N and O-linked glycan
sites found on mammalian proteins [35].
Glyco mine: A predictive method of identifying N, C and O-
linked glycans in the human proteome [2].
KEGG glycan database: A collection of experimentally
determined glycan structures [36].
Sugar Bind DB: Provides information on known
carbohydrate sequences to which pathological organisms
specifically adhere [37].
Symbol nomenclature for glycans (SNFG): A universal
symbol nomenclature for the graphical representation of
glycan structures [38].
UNiCarbKB: An information storage and search platform for
glycomics and glycobiological research [39].
Table 1: Current tools available for glyco-immuno-oncological
research.
Tool Pros Cons
Plant lectins Cheap and easy to use.
Good sensitivity.
Limited specificity.
Gives no information
regarding scaffold
protein.
Recombinant human
lectins
Often tagged, these
tools are a good
starting point for
interaction studies.
Expensive
Glycan specific
antibodies
Often more specific
than lectins.
Often IgM which can
cause problems w.r.t.
application.
Glyco-form specific
glycoprotein
antibodies
Very specific owing to
need for both glycan
and peptide to be
present for binding to
occur. Often extremely
sensitive.
Difficult to develop.
Chemically
synthesized
glycopeptides
Easy to produce many
glycans. Cheap.
Difficulty in producing
some sugars, and, by
nature short.
Polyacrylamide
linked glycans
Long chains of
repeated uniform
glycans allow for
maximal avidity for
binding studies.
Biological relevance
can be questioned.
Recombinant
glycoforms of
glycoproteins
The most biologically
relevant tool for
studying glycoform
specific responses to
specific glycoproteins.
Expensive and time-
consuming to produce.
Difficulties in producing
glycoproteins with
complex glycans.
Mass Spectrometry Unparalleled sensitivity
and specificity for
glycan determination
and quantification.
Difficult to use for high
throughput studies –
although becoming
increasingly possible.
Expensive and time
consuming.
Transfected,
transduced, mutated
or engineered cell
lines, including
GlycoDisplay and
glycocalyx editing
Biologically relevant
and, for simple glycans,
extremely robust.
There are often
technical and biological
problems when
expressing complex
glycans.
The Future
In recognition of the weight of evidence that supports the
importance of glycans in cancer development, especially in the
light of the impact on the immune compartment, the need for
glyco-phenotyping is being voiced strongly [29]. By using lectin
and transcriptomic approaches, and possibly high throughput
mass spectrometry of specific ‘signpost’ glycopeptides, it
would be possible to develop a new method of categorizing
tumors [40,41]. If certain signatures were associated with
specific form of glyco-immune modulation then appropriate
glycan or glycoform-specific therapies would be given. This
may, in some quarters be seen slightly regressive, as we are
moving into DNA and RNA dominated personalized medicine,
but it is logical.
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Therapies are being developed even without such a
paradigm shift; there are several groups, and increasing
number of biotechs, working on inhibiting glycan-immune
modulation and targeting specific glycoforms of commonly
expressed and disease-relevant glycoproteins [29,42]. It is a
sensible move in a crowded therapeutic marketplace; however
translation of this biology is likely to be difficult. Many of these
mechanisms are known, or believed, to be vital for immune
homeostasis, therefore drug-induced systemic dysregulation
has the potential to invoke profound side-effects. Further to
this it should not be forgotten that these glycoforms, and their
effects, have a healthy physiological role – so although
targeting the glycan and the protein achieves much greater
specificity and sensitivity than the protein alone, we cannot
become complacent and assume absolute specificity.
At this point, it is additionally important to draw your
attention to two potential issues that need to be addressed in
the near future. Firstly, the majority of recombinant proteins
for clinical and research use are manufactured in Chinese
hamster ovary (CHO) cells (K1 clone) – these are cells that
cannot O-glycosylated beyond sialylated core 1 [43]. Clearly
these therapies work, however, could they be better if
expressed in systems that carry the glyco-machinery for a
different glycophenotype? Are there therapies that never
made it to the clinic because although the protein was correct,
their glycans inhibited their functionality?
Secondly, the impact of glycans on antibody-epitope
recognition has not been fully explored; data using antibodies
that shows quantitative or even qualitative differences may
simply be a result of a glycan change within the target epitope.
Our group has seen glycan dependant differential binding
curves, in recognition of the antigenic PDTR epitope within the
MUC1 tandem repeat, since the 1980s [44]. This is not new, it
is just niche; we all need to be aware that any epitope which
contains a serine, threonine or an appropriately flanked
asparagine (Asn-X-Ser, Asn-X-Thr or Asn-X-Cys) should be
considered ‘changeable’ by glycan alterations.
Although both of the above examples are slightly alarming,
they are surmountable, and they are beginning to be
addressed. Indeed, we are seeing the emergence of a new
class of glycoform specific antibodies and chimeric antigen
receptors for potential therapeutic use, and glycoengineering
of CHO cells to address specific needs [19,28,45,46].
Conclusion
With improving resources and growing interest and
investment, the future looks bright for this field. Glycobiology
in the context of immunology and oncology should not be
ignored, and instead be championed and understood. There
are many, many more discoveries to be made as we begin to
unpick this fascinating, and occasionally frustrating, ultimate
level of biological information.
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